Trial results

Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)

NCT02055014 on ClinicalTrials.gov · last registry update 2016-04-26

72 participants. Its estimated completion date, March 2017, has passed with no update to the record. Primary outcome, as filed: Glycated haemoglobin (HbA1c). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. liraglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

UNKNOWN

Phase

P4

Drug

liraglutide

Saxenda, Victoza, Xultophy

Sponsor

Sandwell & West Birmingham Hospitals NHS Trust

Sponsor type

Other

Enrollment

72

Started

2013-07

Primary completion

2017-03 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Glycated haemoglobin (HbA1c)

Conditions studied

Type 2 Diabetes · Obesity · Diabesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.